SAVACassava Sciences, Inc.

$116M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$16M

Operating Income

-$20M

Net Income

$25M

EPS (Diluted)

$-0.43

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$77M

Stockholders' Equity

$79M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$16M	-$22M	+26.6%
Operating Income	-$20M	-$27M	+24.8%
Net Income	$25M	-$24M	+203.2%

SAVA Q1 2024 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena